AbbVie's $10.9B Apogee Buy Targets Dupixent; 1st Solid Tumor CAR-T Approved in China

Pfizer's forty-three-billion-dollar Seagen bet takes another hit — sigvotatug vedotin fails in Phase 3 non-small cell lung cancer.

CMS blinks on Opzelura classification, Sangamo shuts down after thirty years, and Moderna's flu shot clears a panel unanimously. Let's get into a loaded Tuesday.

Welcome to The Pharma Closeout for Tuesday, June twenty-third, twenty twenty-six. I'm Alex Mercer.

And I'm Maya Patel.

Top story. Pfizer posted topline Phase 3 results for sigvotatug vedotin in previously treated metastatic non-squamous non-small cell lung cancer — and the drug disappointed. This ADC came directly from the forty-three-billion-dollar Seagen acquisition. Both Endpoints News and BioPharma Dive are framing this as the Seagen bet souring further, signaling this is not an isolated miss.

Non-squamous NSCLC after IO progression is essentially an ADC graveyard. The heterogeneity of target expression in that setting makes it one of the hardest tumor types to crack with this modality. So the failure itself doesn't surprise me — what it does is tighten the aperture on where this platform can still deliver.

Right, and I think it's worth lingering on what that narrowing really means from a portfolio-strategy standpoint. When you spend forty-three billion dollars, you're not buying a single drug — you're buying optionality across a dozen or more tumor types. Every time one of those options expires worthless, the implied value of the remaining programs has to carry a heavier load. That math gets punishing fast.

Exactly. And the clinical challenge compounds it. Lung cancer is one of the largest addressable markets in solid-tumor oncology — arguably the largest in terms of patient volume and commercial opportunity. Taking that off the table doesn't just remove one program; it removes the single highest-ceiling indication for this particular ADC. You can't replace that kind of revenue potential with a bladder cancer label, even a good one.

And the internal dynamics compound the pressure further. Pfizer announced a CFO transition effective August fifteenth, closed the ten-billion-dollar Innovent oncology collaboration just last month — they're pulling in external assets to supplement a pipeline that needs wins. Every ADC miss from the Seagen portfolio shrinks the pool of indications that can generate the growth Pfizer needs to justify that premium.

If the platform delivers in breast or bladder — indications where ADCs have shown more consistent activity — the narrative recovers. But the lung failure loads more weight onto fewer remaining programs. And Daiichi Sankyo and AstraZeneca are setting the pace in ADC oncology right now. Their clinical packages in solid tumors are getting harder to match with every new data cut.

That competitive dynamic is the part that doesn't get enough attention. It's not just whether Pfizer's ADC programs succeed in absolute terms — it's whether they succeed relative to a field that's moving very quickly. If your competitors are generating confirmatory data across multiple tumor types while you're absorbing Phase 3 failures, the commercial window narrows even when the science eventually works. You're late to a market someone else has already shaped.

And payers notice that. Reimbursement leverage goes to the ADC with the broadest label and the deepest evidence package. Second-to-market in oncology with a narrower dataset means lower pricing power, tighter formulary access, and a longer runway to peak sales. That's the compounding problem Pfizer faces here.

The daily stock move isn't the scoreboard here. What matters is whether the Seagen platform can produce enough wins across the full ADC portfolio to justify forty-three billion dollars. Right now, the win column is getting thinner.

The sharper way to read this: Pfizer didn't just buy drugs — they bought a platform thesis. Platform theses live or die on hit rate across indications. One more failure in a high-value tumor type, and the conversation shifts from patience to write-down risk.

That write-down conversation applies to companies too — not just portfolios. Sangamo Therapeutics is closing its doors after roughly three decades. One of the original pioneers in programmable gene editing with zinc-finger nuclease technology. Eli Lilly and Astellas Pharma are reportedly eyeing its assets. No sale price disclosed yet.

The zinc-finger platform never achieved commercial escape velocity, but the IP carries real value for anyone building editing tools beyond CRISPR. Lilly and Astellas both have active gene therapy programs — whether this becomes a competitive bidding situation or a quiet carve-out reveals a lot about how legacy biotech IP gets priced in this market.

And there's an interesting strategic subtlety here. For a buyer like Lilly, this isn't necessarily about deploying zinc-finger nucleases as a primary modality — it could be about owning freedom-to-operate around editing approaches that sit outside the CRISPR patent thicket. That kind of IP optionality has a different value calculus than a straightforward pipeline acquisition.

Which is exactly why the sale price, whenever it's disclosed, will be instructive. If the number comes in well below what you'd expect for a clinical-stage platform, it tells you the market is pricing the IP purely on near-term clinical utility. If it comes in higher, someone is paying for strategic positioning — and that says something about where the gene-editing space is headed beyond CRISPR.

Two startup launches worth flagging. Bionyra came out with a hundred and sixty-five million for next-generation immune drugs — co-founded by Sofinnova Partners and a former Sanofi immunology R&D head. That Sanofi connection is interesting because Sanofi's current R&D chief Houman Ashrafian is also departing, per BioPharma Dive. That's a meaningful leadership gap at a top-five pharma R&D organization.

And it raises the broader question of institutional continuity. When senior R&D leadership turns over at a company of Sanofi's scale, it creates uncertainty about pipeline priorities, development timelines, and strategic direction. The fact that former Sanofi talent is already launching new ventures with significant capital suggests the ecosystem is absorbing that talent quickly — but it doesn't replace the disruption inside the organization itself.

And Osanni Bio pulled in a hundred and ninety million for ophthalmology and cardiology programs. Three hundred and fifty-five million in new venture money across two launches in a single day — the financing window isn't just open, it's propped open.

What stands out to me is the breadth of therapeutic focus across those two launches — immunology, ophthalmology, cardiology. This isn't capital chasing a single hot modality. It's a signal that venture investors see opportunity across multiple verticals, which historically correlates with sustained funding cycles rather than speculative spikes.

The public markets are reinforcing that. Healthcare gained one point three one percent today while the S&P five hundred dropped one point four four. JNJ up three point three seven percent, Merck up three point five seven, Abbott up three point zero seven. Merck's move likely reflects the Prometheus IBD data coming through. When pharma outperforms the broader market by nearly three full points on a down day, capital is making a directional statement.

XBI is up over twenty percent year-to-date. That kind of broad-based biotech strength running alongside big-pharma defensive flows isn't a simple risk-off rotation — there's genuine pipeline conviction underneath it. You don't get both large-cap pharma and small-cap biotech moving in the same direction unless allocators believe the fundamental story — meaning clinical catalysts and regulatory clarity — supports both ends of the market-cap spectrum.

On the regulatory front — three stories, but the CMS settlement deserves the most attention. Incyte dropped its lawsuit against the agency, and CMS agreed not to bundle Opzelura — topical ruxolitinib for atopic dermatitis — with Jakafi, the oral formulation used in hematology.

Break down the commercial mechanics for us.

If CMS had bundled them, Opzelura would have inherited Jakafi's rebate history under Medicare Part D. Same active molecule, completely different formulation, different indication, different route of administration — but CMS was classifying them as one product for pricing purposes. That would have torpedoed Opzelura's commercial viability at current price points. Incyte challenged it, and CMS conceded. The precedent here is broad — any company developing a topical, inhaled, or reformulated version of an existing systemic molecule now has a reference case for how CMS should treat classification. That's a meaningful shield.

And from a strategic planning perspective, this settlement doesn't just protect Incyte — it de-risks an entire category of lifecycle innovation. If you're a pharma company sitting on a systemic molecule and evaluating whether to invest in a topical or inhaled reformulation for a different therapeutic area, this CMS outcome materially changes your go/no-go calculus. Before this, bundling risk was a legitimate reason to kill those programs. That friction is now substantially reduced.

Which is exactly the kind of second-order effect that doesn't show up in Incyte's stock price but reshapes pipeline decisions industry-wide over the next several years.

Staying with the FDA. Regenxbio will resubmit its gene therapy application after the agency reversed another Makary-era rejection. Per BioPharma Dive, these were decisions that appeared to contradict earlier agreements between the agency and drugmakers. UniQure is also moving to file a gene therapy for approval, reflecting the same shift. This is now a clear pattern of institutional correction at the agency.

These weren't speculative applications — they were programs where sponsors had pre-negotiated terms with the FDA. Each reversal reopens a filing window the market had written off. For the gene therapy sector broadly, this is a de-risking catalyst that hasn't been fully priced in. The reason I say it's not fully priced is that each individual reversal gets treated as a company-specific event, but the pattern tells you something systemic — the agency is actively unwinding a set of decisions, and that benefits every sponsor whose program was caught in the same policy shift.

Also worth noting on the regulatory side — Eli Lilly followed through on its three-forty-B ultimatum, cutting off discounts to hospitals that didn't meet new paperwork requirements. Hospitals are pushing HRSA to intervene. Whether that triggers a legislative response is the open question.

And the Lilly situation is worth watching precisely because it tests the boundaries of manufacturer leverage in the three-forty-B program. If Lilly faces no meaningful regulatory pushback, other manufacturers will follow. If HRSA intervenes aggressively, it redefines the power dynamic between drugmakers and covered entities. Either outcome sets a precedent.

Separately, Moderna's flu vaccine mFlusiva won unanimous support from an FDA advisory committee, with a PDUFA date of August fifth. Unanimous is hard to argue with.

It is. And I'd emphasize what unanimous really means procedurally — it means not a single committee member found a reason to vote against, which in a field as crowded and scrutinized as influenza vaccines is a strong statement about the risk-benefit profile. That doesn't guarantee approval, but it removes the most common source of late-stage regulatory friction.

And a lawsuit landed today accusing Genentech and Novartis of a kickback scheme tied to Xolair. False Claims Act exposure on a blockbuster biologic — that's not a footnote. Finally, Pfizer did get some positive regulatory news: Braftovi won a first-line expansion in Europe, per FiercePharma. A small win on a day when the company needed one.

If mFlusiva converts that unanimous panel vote into approval, Moderna has a fundamentally different revenue story — seasonal demand, not pandemic cycles. August fifth determines whether that story becomes real.

Looking ahead. The Moderna mFlusiva PDUFA on August fifth is the near-term vaccine catalyst. Pfizer's CFO transition takes effect August fifteenth — watch for any strategic messaging around the Seagen portfolio tied to that move. The Sangamo asset process will reveal how the market values legacy gene-editing IP when Lilly and Astellas are both at the table.

And watch the Makary-era reversal pipeline. If two or three more gene therapy applications reopen over the next month, the sector's regulatory risk profile looks materially different by Q3 — and that reprices the entire space.

That's your Pharma Closeout for Tuesday. Sigvotatug vedotin stumbles in lung cancer, CMS backs down on Opzelura, Sangamo closes after thirty years, and healthcare plays defense while the broader market sells off. From Pfizer's ADC setback to mFlusiva's unanimous panel vote, the catalysts keep stacking. If this briefing saves you time, follow us on Spotify and drop a rating — we'll be back tomorrow.

Have a good evening, everyone. See you tomorrow. ## Episode Metadata **Title:** Pfizer Seagen ADC Fails in Lung Cancer Phase 3; CMS Settles Opzelura Classification; Sangamo Shuts Down | Jun 23, 2026 **Description:** Pfizer's sigvotatug vedotin disappoints in Phase 3 NSCLC — another blow to the $43B Seagen deal. Plus CMS settles with Incyte on Opzelura classification, Sangamo Therapeutics closes after 30 years, and Moderna's flu vaccine wins unanimous FDA panel support. **Tags:** Pfizer, Seagen, sigvotatug vedotin, ADC, antibody-drug conjugate, non-small cell lung cancer, NSCLC, Incyte, Opzelura, Jakafi, ruxolitinib, CMS, Medicare Part D, Sangamo Therapeutics, zinc-finger nuclease, gene editing, Eli Lilly, Astellas, Moderna, mFlusiva, flu vaccine, Regenxbio, UniQure, gene therapy, FDA, Makary, Genentech, Novartis, Xolair, Braftovi, encorafenib, 340B, Sanofi, Houman Ashrafian, Bionyra, Osanni Bio, pharma, pharmaceutical, clinical trials, biotech, drug approvals #